Protein kinase inhibitors

Cardiff Oncology to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 20, 2021
Chemical compounds, Clinical medicine, Cancer, Lactams, PLK1, Protein kinase inhibitors, Acute myeloid leukemia, Decitabine, Chemotherapy, CD135, Bemcentinib

Our goal is to overcome resistance, improve response to treatment and increase overall survival.

Key Points: 
  • Our goal is to overcome resistance, improve response to treatment and increase overall survival.
  • We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
  • Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.
  • A Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML) completed enrollment in 2020.

Ribon Therapeutics Announces Oral Presentation of RBN-2397 Clinical Data at 2021 ASCO Annual Meeting

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Protein kinase inhibitors

b'Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • b'Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that data from its first-in-human Phase 1 trial evaluating RBN-2397, its small molecule inhibitor of PARP7, as a monotherapy in patients with advanced solid tumors was selected for an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Presenting the data will be Gerald S. Falchook, M.D., Director, Drug Development, Sarah Cannon Research Institute at HealthONE, Denver, CO and Clinical Investigator in the RBN-2397 Phase 1 trial.
  • Our distinctive approach of targeting stress support pathways is a promising novel strategy for treating multiple types of cancer,\xe2\x80\x9d said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics.
  • RBN-2397 is currently in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors ( NCT04053673 ).

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Chemical compounds, Organic compounds, Protein kinase inhibitors, Breakthrough therapy, Piperazines, G1 Therapeutics, Antiestrogens, Selective estrogen receptor degrader, Trilaciclib, Palbociclib, Small-cell carcinoma

b'RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th.
  • The presentations will describe results from the Company\xe2\x80\x99s study of its oral selective estrogen receptor degrader (SERD), rintodestrant, in combination with palbociclib for the treatment of ER+/HER2- advanced breast cancer as well as data describing the effects of COSELA\xe2\x84\xa2 (trilaciclib) on T-cell activation and clonal expansion in patients with newly diagnosed extensive-stage small cell lung cancer.
  • G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .\nG1 Therapeutics\xe2\x84\xa2 and the G1 Therapeutics logo and COSELA\xe2\x84\xa2 and the COSELA logo are trademarks of G1 Therapeutics, Inc.\n'

Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 18, 2021
Tumors of the hematopoietic and lymphoid tissues, Cancer, Protein kinase inhibitors, Bemcentinib, Carboxylic acids, ETV6

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points: 
  • The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
  • APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
  • Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others.
  • We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.\n'

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Entospletinib, Indazoles, Morpholines, Tyrosine-protein kinase SYK, Enzymes, Acute myeloid leukemia, Tyrosine kinase, NPM1, Protein kinase inhibitors

A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.

Key Points: 
  • A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • For more information, visit www.kronosbio.com or follow the company on LinkedIn .\n'

Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021

Retrieved on: 
Wednesday, May 5, 2021
Chemical compounds, Branches of biology, Drugs, Protein kinase inhibitors, Piperazines, Aromatase inhibitors, Progonadotropins, Cyclin-dependent kinase 4, Oncogenes, Letrozole, Breast cancer, Nonsteroidal

Patients who have metastatic breast cancers that progress on estrogen receptor blocking agent and CDK4/6 inhibitor therapies are a group in which we need to define the most optimal drug treatment.

Key Points: 
  • Patients who have metastatic breast cancers that progress on estrogen receptor blocking agent and CDK4/6 inhibitor therapies are a group in which we need to define the most optimal drug treatment.
  • Enobosarm is in clinical development for the treatment of metastatic ER+HER2- breast cancer patients whose disease has progressed after treatment with a nonsteroidal aromatase inhibitor (anastrozole or letrozole), fulvestrant, and a CDK4/6 inhibitor.
  • In the U.S., FC2 is available by prescription through multiple third-party telemedicine and internet pharmacy providers and retail pharmacies.
  • An NDA was filed by FDA in April 2021 with a PDUFA date in December 2021.

Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.

Retrieved on: 
Wednesday, May 5, 2021
Aromatic compounds, Tyrosine kinase inhibitor, Organic compounds, Chemical compounds, TKI, Chloroarenes, Aromatic amines, Quinazolines, Protein kinase inhibitors, Lestaurtinib, Matuzumab

The clinical data, presented at the American Society of Clinical Oncology (ASCO)1, demonstrated that the treatment was well-tolerated and produced clinical activity.

Key Points: 
  • The clinical data, presented at the American Society of Clinical Oncology (ASCO)1, demonstrated that the treatment was well-tolerated and produced clinical activity.
  • Recently, a patent covering the use of Milciclib in combination with a tyrosine kinase inhibitor (TKI) or other drugs was granted2.
  • The granted claims provide complete freedom to further develop a combination of Milciclib with an approved TKI for treatment of patients with advanced HCC or other cancers.
  • Takanawa also supports companies entering the Japanese and Asian market as well as Japanese companies to enter overseas markets.

G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021

Retrieved on: 
Wednesday, April 28, 2021
Life sciences, Organic compounds, Biotechnology, G1 Therapeutics, Protein kinase inhibitors, Trilaciclib, Biopharmaceutical

b'RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET.\nThe live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 2509548.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET.\nThe live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 2509548.
  • The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com .\nG1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company\xe2\x80\x99s first commercial product, COSELA\xe2\x84\xa2 (trilaciclib).
  • G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.\nG1 Therapeutics\xe2\x84\xa2 and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.\n'

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021  

Retrieved on: 
Monday, April 26, 2021
Clinical medicine, Medicine, CD135, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Leukemia, Protein kinase inhibitors, Lactams, Phosphoinositide 3-kinase inhibitor, Toralizumab

b"The live conference call can also be accessed through a link on the Investor Relations section of Aptose\xe2\x80\x99s website at https://www.aptose.com/investors/news - events/ir - calendar .

Key Points: 
  • b"The live conference call can also be accessed through a link on the Investor Relations section of Aptose\xe2\x80\x99s website at https://www.aptose.com/investors/news - events/ir - calendar .
  • An archived version of the webcast along with a transcript will be available on the company\xe2\x80\x99s website for 30 days.\nThe press release, the financial statements and the management\xe2\x80\x99s discussion and analysis for the year and quarter ended March 31, 2021 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml .\nAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
  • The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
  • The Company has two clinical- stage investigational products for hematologic malignancies: luxeptinib (formerly CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).\n"

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

Retrieved on: 
Wednesday, April 21, 2021
Chemical compounds, Protein kinase inhibitors, Dennis Slamon, Translational research, Ribociclib

b'EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC).

Key Points: 
  • b'EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) -- Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC).
  • Accomplishing this during an evolving global pandemic speaks to the strength of our global clinical trial network and the entire TRIO team,\xe2\x80\x9d stated Dennis J. Slamon, MD, PhD, TRIO Chairman/Executive Director and Director of Clinical Translational Research at the University of California, Los Angeles Jonsson Comprehensive Cancer Center.
  • \xe2\x80\x9cWe appreciate and thank the clinical investigators, trial coordinators and of course the patients for their participation and contributions.
  • Additional information on TRIO can be found by visiting https://www.trioncology.org .\nInterested parties may also follow TRIO on Twitter ( twitter.com/TRIOncology ) or LinkedIn at TRIO - Translational Research in Oncology.\n'